Major Milestone Reached: COVend’s IXION 2.0 trial enrols its first patients!

We are excited to announce the start of patient enrollment for the IXION 2.0 clinical trial at the Goethe University Hospital Frankfurt. Due to the evolving dynamics of COVID-19, the project’s focus has shifted to investigating the potential benefits of the FX06 drug for patients with acute respiratory distress syndrome (ARDS). Spearheaded by Prof. Zacharowski and Dr. Petra Wülfroth, the co-founder of F4 Pharma in Vienna, the consortium and clinical trial were restructured in record time, underlining the unwavering joint commitment to innovative medical research in critical health conditions.

ARDS: A Global Challenge

ARDS is a significant medical issue with no currently available drug-based treatments. It can occur due to various factors, such as viral or bacterial infections, severe trauma, major surgery, or blood transfusions. In ARDS patients, the exchange of gases in the lungs is hindered by damaged alveoli, dysfunctional capillaries, and fluid build-up. Despite ongoing research, there is no effective drug treatment available, highlighting the urgent need for new therapeutic approaches.

Introducing our Solution: FX06 Precision Therapy

FX06, a naturally occurring fibrin fragment in the human body, introduces a novel mechanism of action targeting the molecular origin of ARDS. It binds to vascular endothelial cadherin, a molecule at the surface of the endothelial cells lining the inside of capillaries. FX06 has an anti-inflammatory and capillary-protecting effect and can thus counteract the vicious spiral that progressively worsens the patient’s condition.

Our IXION 2.0 Clinical Study

The COVend project brings together clinicians, biochemists, data scientists, and economists to gain a comprehensive understanding of ARDS and identify effective treatment strategies for real-world scenarios. The IXION2.0 study is an exploratory, randomised, placebo-controlled, double-blind, parallel phase II clinical trial. IXION2.0 is being conducted in five European countries (France, Germany, Lithuania, Romania and Spain) and is open to patients of all genders and all ethnicities, ensuring a diverse study population representative for all European citizens.


In the face of complex healthcare challenges, the COVend consortium’s multidisciplinary and innovative approach is a testament to the power of scientific collaboration, diversity, and collective resilience in pushing the boundaries of medicine. Stay informed on the latest progress and advancements happening in COVend.

For more information on IXION 2.0, please visit the dedicated webpage on our COVend website.